Based in Redwood City, California, Arginox Pharmaceuticals specializes in the research and development of breakthrough drugs for treating cardiovascular pathologies in hospitalized patients. Their flagship product, Tilarginine Acetate Injection, inhibits the production of nitric oxide and is used for the treatment of cardiogenic shocks. With a strong emphasis on manufacturing cardiovascular drugs for multiple therapeutic areas, Arginox Pharmaceuticals is an emerging specialty biopharmaceutical company.